The Investec Boosts AstraZeneca plc (AZN) Price Target to GBX 5,000

The Investec Boosts AstraZeneca plc (AZN) Price Target to GBX 5,000

AZN has been the topic of several other reports. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,100 ($65.51) price objective on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC restated an “overweight” rating and set a GBX 6,000 ($77.07) price objective on shares of AstraZeneca plc in a research report on Friday, April 28th. Berenberg Bank cut their price objective on shares of AstraZeneca plc from GBX 5,500 ($70.65) to GBX 5,450 ($70.01) and set a “buy” rating for the company in a research report on Tuesday, February 21st. Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,500 ($70.65) price target on shares of AstraZeneca plc in a research report on Wednesday, March 15th. Finally, Societe Generale reiterated a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, March 23rd. Six investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of GBX 5,026.80 ($64.57).

AstraZeneca plc (LON:AZN) had its target price boosted by equities research analysts at Investec from GBX 4,600 ($59.09) to GBX 5,000 ($64.23) in a research report issued on Friday, May 26th. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Investec’s price target indicates a potential downside of 6.91% from the company’s current price.

AstraZeneca plc (LON:AZN) opened at 5381.00 on Friday. The firm’s market cap is GBX 68.12 billion. The firm’s 50-day moving average price is GBX 4,912.60 and its 200-day moving average price is GBX 4,614.19. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.

AstraZeneca plc Company Profile AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment